VACH · Voyager Acquisition Corp./Cayman Islands - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - |
| SG&A | $10.0K | - | $405.8K | $240.9K | $10.0K | - | $10.0K | $50.8K |
| Total Operating Expenses | - | - | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - | - | - |
| Operating Income | ($265.0K) | - | ($405.8K) | ($50.8K) | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - |
| Net Income | $180.5K | - | $2.36M | ($50.8K) | ($52.0K) | - | $1.32M | ($50.8K) |
| EPS - Basic | - | - | - | - | - | - | - | ($0.01) |
| EPS - Diluted | - | - | - | - | - | - | - | ($0.01) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $133.8K | $182.1K | $252.3K | $92.5K | $445.5K | $668.3K | $757.9K | $25.0K |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - |
| Current Assets | $44.3K | $193.6K | $263.9K | $303.4K | $501.1K | $712.3K | $784.9K | $25.0K |
| Total Assets | $272.28M | $270.06M | $267.55M | $264.82M | $262.29M | $259.81M | $256.88M | $392.4K |
| Current Liabilities | $274.68M | $1.29M | $491.3K | $125.9K | $86.2K | $39.0K | $30.0K | $76.7K |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Total Liabilities | $286.73M | $13.34M | $12.54M | $12.17M | $12.13M | $12.08M | $12.07M | - |
| Stockholders' Equity | ($15.34M) | ($13.15M) | ($12.27M) | ($11.87M) | ($11.63M) | ($11.37M) | ($11.29M) | ($5.0K) |
| Retained Earnings | ($15.34M) | ($13.15M) | ($12.27M) | ($11.87M) | ($11.63M) | ($11.37M) | ($11.29M) | ($107.8K) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($149.3K) | - | - | - | ($222.8K) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | $25.0K | - | - | - |
| CapEx | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | 0.1% | - | 0.9% | -0.0% | -0.0% | - | 0.5% | -12.9% |
| Return on equity | -1.2% | - | -19.2% | 0.4% | 0.4% | - | -11.7% | 1016.2% |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 0.00 | 0.15 | 0.54 | 2.41 | 5.81 | 18.28 | 26.16 | 0.33 |
| Quick ratio | 0.00 | 0.15 | 0.54 | 2.41 | 5.81 | 18.28 | 26.16 | 0.33 |
| Cash ratio | 0.00 | 0.14 | 0.51 | 0.73 | 5.17 | 17.15 | 25.26 | 0.33 |
| Leverage | ||||||||
| Debt / Equity | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - |
| Equity multiplier | -17.75 | -20.54 | -21.80 | -22.32 | -22.55 | -22.85 | -22.75 | -78.48 |
| Liabilities / Assets | 1.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | - |
| Efficiency | ||||||||
| Asset turnover | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | - | - | 78.5% | 0.0% | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -31.9% | -15.6% | -8.7% | -237249.4% | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Voyager Acquisition Corp./Cayman Islands against the 5 most active filers in the same SIC group.